Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Epilepsy × enzalutamide × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 164 Neoplasm Metastasis 20 Prostatic Neoplasms, Castration-Resistant 19 Breast Neoplasms 18 Neoplasms 15 Metastatic Castration Resistant Prostate Cancer 9 Prostate Cancer Metastatic 7 Metastatic Castration-Resistant Prostate Cancer 7 Triple Negative Breast Neoplasms 5 Parkinson Disease 4, Autosomal Dominant Lewy Body 4 Pancreatic Neoplasms 4 Metastatic Castration-resistant Prostate Cancer 4 Melanoma 4 Carcinoma, Non-Small-Cell Lung 4 Squamous Cell Carcinoma of Head and Neck 3 Small Cell Lung Carcinoma 3 Prostate Adenocarcinoma 3 Colorectal Neoplasms 3 Castration-resistant Prostate Cancer 3 Carcinoma, Hepatocellular 3 Adenocarcinoma 3 mCRPC 2 Uterine Cervical Neoplasms 2 Urinary Bladder Neoplasms 2 Recurrence 2 Ovarian Neoplasms 2 Non-metastatic Castration-resistant Prostate Cancer 2 Metastatic Hormone-sensitive Prostate Cancer 2 Metastatic Hormone Sensitive Prostate Cancer 2 Metastatic Castration-resistant Prostate Cancer (mCRPC) 2

Interventions

Sirolimus 4 LY3295668 erbumine 3 Everolimus 3 Medical Marijuana 2 Anticonvulsants 2 ziprasidone 1 perampanel 1 enzalutamide 1 clevidipine 1 brivaracetam 1 Zolpidem 1 Warfarin 1 Vigabatrin 1 Vecuronium Bromide 1 Vancomycin 1 Tranexamic Acid 1 Topotecan 1 Tobramycin 1 Therapeutic Touch 1 Temozolomide 1 TAS-119 1 Surgical Procedures, Operative 1 Sulfasalazine 1 Spironolactone 1 Sevoflurane 1 Sevelamer 1 Saline Solution 1 Rocuronium 1 Registries 1 Radiotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04290611 2023-04-13

VENDY

Groupe Hospitalier Pitie-Salpetriere

500,000 enrolled

Brain Diseases, Epilepsy, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡